Showing results (901-910 of 1,194) with videos related to
Sort By:
Pageof 120
Pharmaceutical Statistics|April 28, 2021
Using marginal structural models to analyze the impact of subsequent therapy on the treatment effect in survival data: Simulations and clinical trial examplesQing Xu, Donna PrzepiorkaPharmaceutical Statistics|May 21, 2021
The individual-level surrogate threshold effect in a causal-inference setting with normally distributed endpointsWim Van der Elst, Ariel Alonso Abad, Hans Coppenolle, et al.Pharmaceutical Statistics|May 13, 2015
Testing drug additivity based on monotherapiesHarry Yang, Steven J Novick, Wei ZhaoPharmaceutical Statistics|May 19, 2015
Structured Benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologiesShahrul Mt-Isa, Mario Ouwens, Veronique Robert, et al.Pharmaceutical Statistics|May 20, 2015
Assessing switchability for biosimilar products: modelling approaches applied to children's growthRossella Belleli, Roland Fisch, Didier Renard, et al.Pharmaceutical Statistics|April 28, 2020
Methods for clarifying criteria for study continuation at interim analysisLaura E Wiener, Anastasia Ivanova, Gary G KochPharmaceutical Statistics|May 7, 2020
Estimands and inference in cluster-randomized vaccine trialsKayla W Kilpatrick, Michael G Hudgens, M Elizabeth HalloranPharmaceutical Statistics|May 18, 2021
Selection bias, investment decisions and treatment effect distributionsStig Johan Wiklund, Carl-Fredrik BurmanPharmaceutical Statistics|May 19, 2021
The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trialsYanhong Zhou, Ruitao Lin, J Jack LeePharmaceutical Statistics|August 16, 2021
Heterogeneity in treatment effects across diverse populationsBridget M Nugent, Rajanikanth Madabushi, Barbara Buch, et al.Pageof 120